What the results of Wegovy’s longest clinical trial yet show about ...
WEBMay 13, 2024 — New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe...
At least 25,000 people in the US are starting weight-loss drug Wegovy …
WEBMay 2, 2024 — Drugmaker Novo Nordisk said it’s been increasing supply of its sought-after weight-loss drug Wegovy, with at least 25,000 people now starting to take the medicine each week in the United States....
Wegovy users keep weight off for 4 years, new analysis finds - NBC News
WEBMay 14, 2024 — Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker’s case to insurers and governments to cover...
Weight-loss drug Wegovy produces ‘largest benefit ever seen’ …
WEBAug 25, 2023 — The study of 529 patients, funded by drugmaker Novo Nordisk, found that a 2.4-milligram weekly dose of semaglutide, sold as Wegovy for weight loss, led to an improvement of 17 points on a...
Wegovy patients maintain weight loss for 4 years: Novo Nordisk study - CNBC
WEBMay 14, 2024 — Patients taking Novo Nordisk ’s obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis published Tuesday from the longest clinical...
Novo's Wegovy shows heart benefit alongside weight loss in trial
WEBAug 8, 2023 — Wegovy maker Novo Nordisk said on Tuesday a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of...
Wegovy's heart benefits due to more than weight loss, Novo says
WEBPHILADELPHIA, Nov 11 (Reuters) - Novo Nordisk (NOVOb.CO) on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone,...
Weight-loss drug Wegovy cuts risk of stroke, heart attacks ... - NBC News
WEBAug 8, 2023 — The popular obesity drug Wegovy cuts the risk of cardiovascular events, such as heart attack and stroke, by 20%, drugmaker Novo Nordisk said Tuesday.
Obesity drug Wegovy cut risk of serious heart problems by 20%: …
WEBNov 11, 2023 — The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.
Weight loss drug Wegovy slashes risk of serious heart complications - CNBC
WEBNov 11, 2023 — Novo Nordisk’s Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely watched trial, demonstrating a particularly large effect on...
- Some results have been removed